American Association for Cancer Research
10780432ccr183516-sup-211193_2_supp_5388263_p21ntg.pdf (1.53 MB)

Figure S2 from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction

Download (1.53 MB)
journal contribution
posted on 2023-03-31, 21:10 authored by Sofía Carbajosa, María Florencia Pansa, Natalia S. Paviolo, Andrés M. Castellaro, Diego L. Andino, Ayelén D. Nigra, Iris Alejandra García, Ana C. Racca, Lucía Rodriguez-Berdini, Virginia Angiolini, Laura Guantay, Florencia Villafañez, María Belén Federico, María Celeste Rodríguez-Baili, Beatriz L. Caputto, Gerard Drewes, Kevin P. Madauss, Israel Gloger, Elmer Fernandez, Germán A. Gil, José Luis Bocco, Vanesa Gottifredi, Gastón Soria

Legends included in the figure file






National Institute of Cancer



BRCA1 and BRCA2 deficiencies are widespread drivers of human cancers that await the development of targeted therapies. We aimed to identify novel synthetic lethal relationships with therapeutic potential using BRCA-deficient isogenic backgrounds. We developed a phenotypic screening technology to simultaneously search for synthetic lethal (SL) interactions in BRCA1- and BRCA2-deficient contexts. For validation, we developed chimeric spheroids and a dual-tumor xenograft model that allowed the confirmation of SL induction with the concomitant evaluation of undesired cytotoxicity on BRCA-proficient cells. To extend our results using clinical data, we performed retrospective analysis on The Cancer Genome Atlas (TCGA) breast cancer database. The screening of a kinase inhibitors library revealed that Polo-like kinase 1 (PLK1) inhibition triggers strong SL induction in BRCA1-deficient cells. Mechanistically, we found no connection between the SL induced by PLK1 inhibition and PARP inhibitors. Instead, we uncovered that BRCA1 downregulation and PLK1 inhibition lead to aberrant mitotic phenotypes with altered centrosomal duplication and cytokinesis, which severely reduced the clonogenic potential of these cells. The penetrance of PLK1/BRCA1 SL interaction was validated using several isogenic and nonisogenic cellular models, chimeric spheroids, and mice xenografts. Moreover, bioinformatic analysis revealed high-PLK1 expression in BRCA1-deficient tumors, a phenotype that was consistently recapitulated by inducing BRCA1 deficiency in multiple cell lines as well as in BRCA1-mutant cells. We uncovered an unforeseen addiction of BRCA1-deficient cancer cells to PLK1 expression, which provides a new means to exploit the therapeutic potential of PLK1 inhibitors in clinical trials, by generating stratification schemes that consider this molecular trait in patient cohorts.